Company profile: Octant
1.1 - Company Overview
Company description
- Provider of a cellular intelligence platform for studying protein misfolding in human cells and enabling high-throughput screening; multiplexed readouts to measure protein folding and trafficking across hundreds of mutations and conditions; and development of novel therapeutics guided by massive datasets in engineered human cells to improve health and treat disease.
Products and services
- Novel Therapeutics Development: Architects custom-engineered drug programs with novel mechanisms of action guided by massive datasets in engineered human cells
- Cellular Intelligence Platform: Engineers a cell-based system to study protein misfolding in human cells and conduct high-throughput screening directly in that environment
- Multiplexed Read Outs: Produces multiplexed measurements of biological phenomena associated with protein folding and trafficking across hundreds of mutations and conditions
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Octant
IQVIA
HQ: Japan
Website
- Description: Provider of creative solutions for healthcare companies, including clinical development support for pharmaceuticals and medical devices leveraging global and local insights; real-world data consulting; pharmacovigilance services; market data solutions; management consulting with data analytics and M&A support; and technology solutions spanning drug development to commercialization.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full IQVIA company profile →
Seismic Therapeutic
HQ: United States
Website
- Description: Provider of machine-learning technology for immunology drug development, offering the IMPACT platform to accelerate novel biologics by integrating machine learning with structural biology, protein engineering, and translational immunology; Ig Sculpting Enzymes to modify pathogenic antibodies in autoimmune diseases, optimized for reduced immunogenicity while retaining enzyme activity; and Dual-cell Bidirectional antibodies engaging multiple inhibitory pathways in immune cells to restore immune homeostasis.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Seismic Therapeutic company profile →
Eikon Therapeutics
HQ: United States
Website
- Description: Provider of live-cell single-molecule tracking and super-resolution microscopy technologies for drug discovery, offering proprietary hardware, AI and machine learning integration, and custom reagents and automation to enable high-throughput analysis of protein dynamics and interactions, alongside a therapeutic pipeline in oncology, immunology, and neuroscience.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Eikon Therapeutics company profile →
Compendia Bioscience
HQ: United States
Website
- Description: Provider of cancer genomics solutions for oncology research, including bioinformatics to prioritize and annotate driver variants and link biomarkers to curated knowledge; reporting that connects biomarkers to therapies, guidelines, and clinical trials; targeted NGS assays with PCR-based library prep; liquid biopsy tools using cfDNA/ctDNA/CTCs with digital PCR/NGS; and whole exome sequencing via Ion Proton.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Compendia Bioscience company profile →
Transition Bio
HQ: United States
Website
- Description: Provider of condensate technology for drug discovery and diagnostics, offering PhaseScanTM, a microfluidics-based high-throughput molecular screen to identify drug candidates and mechanisms of action; CelPhaseTM, high-content cellular imaging to visualize condensates in disease models and patient samples for target validation; and DeePhaseTM, an AI engine using proprietary datasets for target discovery and hit identification.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Transition Bio company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Octant
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Octant
2.2 - Growth funds investing in similar companies to Octant
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Octant
4.2 - Public trading comparable groups for Octant
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →